GLP-1s and Breast Cancer Risk Signal in Women With Obesity
Two ASCO 2026 real-world studies found lower breast cancer incidence among GLP-1 users, but randomized prevention trials are still needed.
Two observational studies presented at ASCO 2026 suggest that GLP-1 receptor agonist use is associated with lower breast cancer incidence in women with overweight or obesity.
The larger screened cohort found about a 30% lower incidence after matching, while a high-risk cohort found a more modest 16% reduction. These results are encouraging, but they do …
